Images List Premium Download Classic

Hepatitis A

Hepatitis A-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Bisamide derivative of dicarboxylic acid as an agent for stimulating tissue regeneration and recovery of ...
Obschestvo S Ogranichennoi Otvetstvennostiyu "pharmenterprises"
May 31, 2018 - N°20180147184

The invention relates to the field of medicine and concerns an agent that stimulates tissue regeneration and the recovery of diminished tissue and organ function. A medicinal agent for the treatment and/or prophylaxis of a pathological condition selected from the group including metabolic syndrome, impaired glucose tolerance, hepatitis, particularly chronic hepatitis and toxic hepatitis, idiopathic pulmonary fibrosis (ipf), emphysema ...
Compositions and method for detecting hepatitis a virus nucleic acids in single-plex or multiplex assays
Gen-probe Incorporated
March 01, 2018 - N°20180057895

Nucleic acid oligomers specific for human parvovirus genomic dna are disclosed. An assay for amplifying and detecting human parvovirus genotypes 1, 2 and 3 nucleic acid in biological specimens is disclosed.
Probe for detecting virus
Catholic University Industry Academic Cooperation
December 14, 2017 - N°20170356912

The present invention relates to a composition comprising a probe for detecting six representative causative viruses of acute enteritis (norovirus genogroup i and genogroup ii, rotavirus, hepatitis a virus, coxsackievirus, astrovirus, and adenovirus), and a dna microarray, a kit, and a detection method comprising the composition. The present invention is effective due to high specificity and sensitivity to viruses.
Hepatitis A Patent Pack
Download + patent application PDFs
Hepatitis A Patent Applications
Download + Hepatitis A-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Hepatitis A-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Methods of treating liver diseases
Zafgen, Inc.
November 16, 2017 - N°20170326099

The invention provides tricyclic compounds and their use in treating liver disorders, such as non-alcoholic steatohepatitis and related disorders (e.g., fibrosis). The compounds are contemplated to have activity against methionyl aminopeptidase 2..
Methods of lowering serum cholesterol
October 19, 2017 - N°20170296653

Methods of treating subjects having diseases, disorders, or conditions, including disorders associated with cholesterol homeostasis, responsive to agents modulating kupffer cell function, including methods of administration and dosing regimens associated therewith, are provided. Methods of treating subjects having liver diseases, disorders, or conditions, including non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, with an il-10 agent are also provided..
Treatment of herpes, pseudomonas, staph, and hepatitis
September 14, 2017 - N°20170258861

An improved method (process) is provided to treat herpes, pseudomonas, staphylococcus (staph), and hepatitis and help treat or alleviate cold sores, rashes, skin conditions, or symptoms resulting from herpes, pseudomonas, staph, and hepatitis. The method uses a special medicinal composition which can be self-administered and maintained for a prescribed time.
Hepatitis A Patent Pack
Download + patent application PDFs
Hepatitis A Patent Applications
Download + Hepatitis A-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Hepatitis A-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash)
Nusirt Sciences, Inc.
August 24, 2017 - N°20170239253

Methods useful for sustaining a reduction of non-alcoholic steatohepatitis are provided herein. Such methods may comprise administering to a subject in need thereof a sirtuin pathway activator and/or pde5 inhibitor alone or in combination with an amount of a branched amino acid in free amino acid form, or a metabolite thereof.
Novel compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing the same, and ...
Katholieke Universiteit Leuven K.u. Leuven R & D
June 08, 2017 - N°20170158684

The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral ...
Urea compounds and their use as enzyme inhibitors
April 13, 2017 - N°20170101381

Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, ...
Composition for preventing or treating fatty liver diseases
Lg Life Sciences Ltd.
February 09, 2017 - N°20170035776

The present invention relates to a pharmaceutical composition for preventing or treating fatty liver diseases, containing (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1h-indol-7-yl]amine or a pharmaceutically acceptable salt thereof as active ingredients. (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1h-indol-7-yl]amine or a pharmaceutically acceptable salt thereof, according to the present invention, can effectively ...
Compositions and methods for detection of hepatitis a virus nucleic acid
Gen-probe Incorporated
January 12, 2017 - N°20170009284

Nucleic acid oligomeric sequences and in vitro nucleic acid amplification and detection methods for detecting the presence of hav rna sequences in samples are disclosed. Kits comprising nucleic acid oligomers for amplifying and detecting hav nucleic acid sequences are disclosed..
Immunogenic compositions for inhibiting hepatitis d virus
Chrontech Pharma Ab
November 10, 2016 - N°20160324954

Disclosed herein are isolated nucleic acids, compositions of isolated nucleic acids, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include nucleic acids encoding hepatitis b core antigen (hbcag) protein in combination with one or more self-cleavage 2a polypeptides and a second antigenic ...
Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical ...
Katholieke Universiteit Leuven K.u. Leuven R & D
October 13, 2016 - N°20160297789

Disclosed are novel indanone derivatives, pharmaceutically acceptable salts thereof or enantiomers, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of viral diseases, comprising the same as an active ingredient. The indanone derivatives have excellent inhibitory activity against picornaviruses including coxsackie-, entero-, echo-, polio-, and rhinoviruses, as well as exhibiting low cytotoxicity, so that they can ...
Hepatitis A Patent Pack
Download + patent application PDFs
Hepatitis A Patent Applications
Download + Hepatitis A-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Hepatitis A-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Sparc (secreted protein, acidic and rich in cysteine), a new target for the treatment and ...
Asociacion Civil De Estudios Superiores (aces)
July 14, 2016 - N°20160201057

The invention relates to the identification of secreted protein, acidic and rich in cysteine (sparc) as a new therapeutic target in patients with fulminant hepatitis and allows the development of a strategy destined to protect the liver form damage. The invention relates to the treatment of acute liver failure or fulminant hepatitis by administering to a subject in need thereof ...
Treatment of herpes, pseudomonas, staph, and hepatitis
Meritus Corporation
June 02, 2016 - N°20160151436

An improved method (process) is provided to treat herpes, pseudomonas, staphylococcus (staph), and hepatitis and help treat or alleviate cold sores, rashes, skin conditions, or symptoms resulting from herpes, pseudomonas, staph, and hepatitis. The method uses a special medicinal composition which can be self-administered and maintained for a prescribed time.
Antagonists of cb1 receptor
Universite De Bordeaux
May 26, 2016 - N°20160145294

The invention relates to an antagonist of cb1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; ...
Gene signatures of inflammatory disorders that relate to the liver
Institut National De La Recherche Agronomique
March 10, 2016 - N°20160068890

This invention is related to the area of characterization of inflammation in relation with the gut microbiota, in metabolic and autoimmune disorders. In particular, it relates to the identification of gene signatures which can be used as a marker predictive of inflammation associated diseases, such as liver-related metabolic disorders, in particular to the evolution of benign steatosis towards its most ...
Method of producing therapeutic agent
March 03, 2016 - N°20160058778

The present invention relates to a therapeutic agent, wherein the therapeutic agent is d-boramine. The therapeutic agent is prepared by mixing l-carnitine tartrate, pyridoxal 5′ phosphate and fumaric acid.
Methods of treating liver diseases
Zafgen, Inc.
March 03, 2016 - N°20160058731

The invention provides tricyclic compounds and their use in treating liver disorders, such as non-alcoholic steatohepatitis and related disorders (e.g., fibrosis). The compounds are contemplated to have activity against methionyl aminopeptidase 2..
Selective detection of hepatitis a, b, c, d, or e viruses or combination thereof
The Usa, As Represented By The Secretary, Depart- Ment Of Health And Human Services
February 04, 2016 - N°20160032411

Processes and compositions are provided for the detection of hepatitis viruses in a sample. Particular processes and compositions are provided for the selective detection of hdv.
Novel fatty acids and their use in conjugation to biomolecules
February 04, 2016 - N°20160030585

Wherein r1, r2, r3, r4, ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as gdf15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other ...
Loading